A Prospective and Open-Label Study of the Effect on Proximal Tubular Function in Asian-American Patients Receiving Tenofovir Disoproxil Fumarate (TDF) or Entecavir (ETV) for HBV Treatment

Trial Profile

A Prospective and Open-Label Study of the Effect on Proximal Tubular Function in Asian-American Patients Receiving Tenofovir Disoproxil Fumarate (TDF) or Entecavir (ETV) for HBV Treatment

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Entecavir (Primary) ; Tenofovir disoproxil fumarate (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Sponsors New Discovery
  • Most Recent Events

    • 08 Jun 2015 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
    • 08 Jun 2015 Planned primary completion date changed from 1 Oct 2014 to 1 May 2016, as reported by ClinicalTrials.gov.
    • 08 Aug 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top